嵌合抗原受体 T 细胞治疗多发性硬化症：开拓新的前沿领域。
CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier.
机构信息
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Med. 2024 Jun 14;5(6):482-484. doi: 10.1016/j.medj.2024.04.005.
The efficacy of CD19 chimeric antigen receptor (CAR) T cells in B cell malignancies has generated recent interest in their application to other B cell-related pathologies, such as autoimmune diseases. Fischbach et al. report on the use of CD19 CAR T cells in two patients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process.
嵌合抗原受体（CAR）T 细胞在 B 细胞恶性肿瘤中的疗效引起了人们对其在其他 B 细胞相关疾病（如自身免疫性疾病）中的应用的兴趣。Fischbach 等人报告了 CD19 CAR T 细胞在两名进展性多发性硬化症患者中的应用，首次证明了其在该疾病过程中的可行性和安全性。
Zotero 插件